Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $552.20M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.62M
Average 1.43M
ZVRA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Zevra Therapeutics, Inc.NASDAQ: ZVRA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $3.11M fell 0.3% year over year, ahead of the -20.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 27.5% from the prior quarter. Over 3 fiscal years it compounded at +43.3% a year.
Context
- Stock-based compensation amounted to 11.9% of revenue in FY2025, down 51.3 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -0.3% holds above the trailing-twelve-month pace of -20.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.63M USD
- Year-over-year change
- -15.2%
- 4-year CAGR
- +50.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.63M | -15.2% |
| FY2024 | 2024-12-31 | 14.91M | +150.4% |
| FY2023 | 2023-12-31 | 5.95M | +38.7% |
| FY2022 | 2022-12-31 | 4.29M | +76.3% |
| FY2021 | 2021-12-31 | 2.44M | — |
Stock-Based Compensation vs competitors
How ZVRA compares with its peers on the latest reported figures
- ZVRA's LTM Mar 2026 stock-based compensation of $12.62M is the 8th largest of the 11 companies compared; the peer median is $27.08M.
- Its year-over-year change of -20.6% is the 7th highest of 11, against a peer median of -12.5%.
- Stock-based compensation amounts to 10.3% of revenue for ZVRA, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $424.81M | +46.2% | +9.5% | 9.0% | |
| LTM Sep 2026 | $235.1M | +4.2% | +8.0% | 6.4% | |
| LTM Sep 2026 | $64.29M | +20.9% | +38.1% | — | |
| LTM Jun 2026 | $58M | +87.8% | +23.4% | 7.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M | -19.6% | +5.9% | — | |
| LTM Sep 2026 | $21.78M | -76.6% | +1.6% | 1.2% | |
| LTM Mar 2026 | $12.62M | -20.6% | +43.3% | 10.3% | |
| LTM Mar 2026 | $7.02M | -5.4% | +66.3% | — | |
| LTM Mar 2026 | $1.88M | -32.3% | — | — | |
| LTM Mar 2026 | $125K | -78.0% | — | — | |
| Peer median (excluding ZVRA) | $27.08M | -12.5% | +16.5% | 6.7% | |
Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.56M) | (41.54M) | (46.05M) | (105.51M) | 83.23M |
| Depreciation & Amortization | 257K | 944K | 1.01M | 6.39M | 4.05M |
| Deferred Income Tax | 16.2M | 0 | 0 | 15.37M | 3.45M |
| Stock-Based Compensation | 2.44M | 4.29M | 5.95M | 14.91M | 12.63M |
| Change in Working Capital | (357K) | (406K) | 5.88M | (6.64M) | (26.51M) |
| Accounts Receivables | 1.05M | (6.77M) | (9.08M) | 6.87M | (11.98M) |
| Inventory | 0 | 147K | 206K | (8.87M) | (1.31M) |
| Accounts Payables | (1.11M) | 3.13M | 11.13M | (3.6M) | (15.59M) |
| Other Working Capital | (295K) | 3.09M | 3.63M | (1.04M) | 2.36M |
| Other Non-Cash Items | 460K | 17.99M | (329K) | 5.82M | (78.45M) |
| Operating Cash Flow | 10.44M | (18.72M) | (33.54M) | (69.67M) | (1.6M) |
| Capital Expenditures | (102K) | (93K) | (296K) | 0 | (835K) |
| Acquisitions (Net) | 0 | (14.09M) | (30.4M) | 0 | 0 |
| Purchases of Investments | (15.42M) | (22.54M) | (45.81M) | (41.16M) | (309.99M) |
| Sales of Investments | 0 | 36.63M | 59.12M | 25M | 328.5M |
| Other Investing Activities | 0 | (36.63M) | 0 | (6M) | 448K |
| Investing Cash Flow | (15.52M) | (36.72M) | (17.39M) | (22.16M) | 18.13M |
| Debt Repayment | (38.1M) | 12.78M | 25.59M | 16.29M | 0 |
| Common Stock Issued | 49.29M | 324K | 6.32M | 64.52M | 12.44M |
| Common Stock Repurchased | (2.81M) | (4.72M) | (3.45M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 104.74M | 291K | 6.32M | 1.3M | (372K) |
| Financing Cash Flow | 113.11M | 8.35M | 28.46M | 82.11M | 12.06M |
| Effect of Forex Changes | 0 | 204K | 44K | 454K | 28K |
| Net Change in Cash | 108.02M | (46.88M) | (22.42M) | (9.26M) | 28.62M |
| Free Cash Flow | 10.34M | (18.81M) | (33.83M) | (69.67M) | (2.43M) |
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.